What is the role of serologic testing in the workup of diffuse large cell lymphoma?

Updated: Jun 12, 2019
  • Author: Shipra Gandhi, MBBS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

This includes evaluations for hepatitis B virus (HBV), and hepatitis C virus (HCV), and HIV.

Serological evaluation for HBV and HCV is mandatory for those patients expected to receive monoclonal antibody–based therapy (ie, rituximab). As rituximab use has become an integral part of the management of DLBCL, rare but serious adverse events have been associated with hepatitis B and C reactivation. Fatal cases of fulminate hepatic failure due to active hepatitis B or C have been reported in DLBCL patients undergoing chemoimmunotherapy. Therefore, routine HBV and HCV serology is recommended.

In addition, serologic testing for HIV infection should be considered in patients with coexistent HIV risk factors, aggressive histologies (DLBCL, Burkitt or T-cell lymphoma), or unusual clinical presentations.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!